Novartis’ radiopharma gambit; Weight loss battle plays out; Spark co-founder’s new startup; Q1 earnings highlights; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

We are less than two weeks away from the US Pharma and Biotech Summit, where we partner with the Financial Times to interview biopharma leaders, regulators, investors and scientists for unique insights about the year ahead. Learn more and sign up here.

Novartis’ radiopharma gambit

Novartis is once again making moves in radiopharmaceuticals. It announced this week that it will pay $1 billion upfront to acquire Mariana Oncology and the startup’s peptide-based candidates. The buyout came just a couple days after Novartis expanded its deal with PeptiDream, handing the Japanese partner $180…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks